The Biden-Harris Administration Announces New Guidance To Enable Expanded Access To All FDA-Approved Contraceptives Without Cost
Portfolio Pulse from Benzinga Newsdesk
The Biden-Harris Administration has released new guidance to expand access to FDA-approved contraceptives without cost, potentially benefiting 49 million women. Agile Therapeutics, Inc. (NASDAQ:AGRX) commends this move, which aligns with President Biden's June 2023 Executive Order. The guidance aims to eliminate financial barriers to contraceptives, including Agile's product Twirla. The company anticipates working with patients and providers to promote Twirla as a low dose patch contraceptive option.
January 23, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agile Therapeutics may benefit from the new guidance expanding access to contraceptives without cost, as it could increase demand for its product Twirla.
The new guidance directly supports the use of FDA-approved contraceptives, which includes Agile's Twirla. This could lead to increased demand for Twirla, as financial barriers are reduced for 49 million women. The company's positive response to the guidance suggests that they are prepared to capitalize on this opportunity, which may positively impact their short-term stock performance.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90